New cocktail aims to slow aggressive lung cancer
NCT ID NCT07373964
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new combination of drugs (chidamide, a PD-L1 inhibitor, carboplatin, and etoposide) as the first treatment for people with extensive-stage small-cell lung cancer, a fast-growing cancer that has spread. About 36 participants will receive the combination for 4 cycles, then continue chidamide alone to keep the cancer under control. The goal is to see if this approach delays cancer growth and is safe.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of China Medical University
RECRUITINGShenyang, Liaoning, 110001, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can donor immune cells boost lung cancer remission?
- Could adding chest radiation extend life in advanced lung cancer?
- Can a pill restore the Body's tumor suppressor to fight multiple cancers?
- Can a new drug tame advanced solid tumors?
- Can a remote approach bring clinical trials to lung cancer patients?
- Which palliative care approach boosts quality of life in advanced lung cancer?